Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors

US8592425B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Michael D. Altman · Cambridge, US
• Mark T. Bilodeau · Waltham, US
• Jongwon Lim · Lexington, US
• Alan B. Northrup · Reading, US
• Matthew G. Stanton · Marlton, US
• Brandon M. Taoka · Brookline, US

Key dates

• Filing date: Jan 12, 2010
• Grant date: Nov 26, 2013
• Expiry date: Jan 12, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention encompasses imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.